$CDXS
CODEXIS, INC. Stock $cdxs

$cdxs Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000120037520000033 Filed on August 07, 2020

Income Statement

Concept	2020 Q2	2019 Q2	2019 Q1
Revenue	$14.97M	$12.32M	$15.58M
YoY Change	21.5%	-9.0%	10.97%
Cost Of Revenue	$1.699M	$2.772M	$4.391M
YoY Change	-38.71%	6.17%	14.8%
Gross Profit	$13.27M	$9.547M	$11.19M
YoY Change	38.98%	-12.63%	9.54%
Gross Profit Margin	88.65%	77.5%	71.82%
Selling, General & Admin	$8.522M	$7.896M	$8.415M
YoY Change	7.93%	6.77%	8.64%
% of Gross Profit	64.23%	82.71%	75.19%
Research & Development	$10.85M	$8.274M	$8.016M
YoY Change	31.17%	12.27%	11.67%
% of Gross Profit	81.8%	86.67%	71.62%
Depreciation & Amortization	$462.0K	$430.0K	$319.0K
YoY Change	7.44%	65.38%	34.03%
% of Gross Profit	3.48%	4.5%	2.85%
Operating Expenses	$19.38M	$18.94M	$20.82M
YoY Change	2.29%	9.01%	11.06%
Operating Profit	-$6.107M	-$6.623M	-$5.239M
YoY Change	-7.79%	72.56%	11.3%
Interest Expense	$60.00K	$220.0K	$230.0K
YoY Change	-72.73%	29.41%	228.57%
% of Operating Profit
Other Income/Expense, Net	$13.00K	-$88.00K	-$125.0K
YoY Change	-114.77%	7.32%	108.33%
Pretax Income	-$6.037M	-$6.491M	-$5.133M
YoY Change	-6.99%	73.28%	9.31%
Income Tax	$307.0K	$16.00K	$3.000K
% Of Pretax Income
Net Earnings	-$6.344M	-$6.507M	-$5.136M
YoY Change	-2.5%	74.22%	9.42%
Net Earnings / Revenue	-42.39%	-52.82%	-32.96%
Basic Earnings Per Share	-$0.11
Diluted Earnings Per Share	-$0.11	-$118.5K	-$94.89K
COMMON SHARES
Basic Shares Outstanding	59.00M shares	54.54M shares	54.16M shares
Diluted Shares Outstanding	59.00M shares

Balance Sheet

Concept	2020 Q2	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$75.60M	$93.40M	$47.30M
YoY Change	-19.06%	74.25%	94.65%
Cash & Equivalents	$75.65M	$93.42M	$47.32M
Short-Term Investments
Other Short-Term Assets	$3.700M	$2.000M	$1.200M
YoY Change	85.0%	66.67%	-20.0%
Inventory	$686.0K	$720.0K	$633.0K
Prepaid Expenses
Receivables	$26.40M	$11.81M	$12.60M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$106.5M	$110.2M	$63.71M
YoY Change	-3.4%	66.32%	77.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.822M	$5.312M	$4.535M
YoY Change	28.43%	36.8%	73.09%
Goodwill	$3.200M	$3.200M	$3.200M
YoY Change	0.0%	0.0%	-1.27%
Intangibles
YoY Change
Long-Term Investments	$1.000M	$400.0K	$500.0K
YoY Change	150.0%	-42.86%	-28.57%
Other Assets	$391.0K	$207.0K	$1.013M
YoY Change	88.89%	-50.0%	115.53%
Total Long-Term Assets	$35.29M	$36.55M	$37.41M
YoY Change	-3.47%	277.84%	338.1%
TOTAL ASSETS
Total Short-Term Assets	$106.5M	$110.2M	$63.71M
Total Long-Term Assets	$35.29M	$36.55M	$37.41M
Total Assets	$141.8M	$146.8M	$101.1M
YoY Change	-3.41%	93.26%	127.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.637M	$2.164M	$2.180M
YoY Change	21.86%	-29.79%	-16.06%
Accrued Expenses	$6.943M	$4.059M	$7.127M
YoY Change	71.05%	-19.64%	34.37%
Deferred Revenue	$1.903M	$5.851M	$1.554M
YoY Change	-67.48%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$200.0K	$200.0K
YoY Change	-100.0%
Total Short-Term Liabilities	$18.94M	$17.49M	$18.65M
YoY Change	8.31%	6.59%	-13.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$1.246M	$1.222M	$1.320M
YoY Change	1.96%	-23.24%	-24.96%
Total Long-Term Liabilities	$1.246M	$1.222M	$1.320M
YoY Change	1.96%	-31.15%	-34.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.94M	$17.49M	$18.65M
Total Long-Term Liabilities	$1.246M	$1.222M	$1.320M
Total Liabilities	$47.00M	$48.11M	$49.91M
YoY Change	-2.31%	105.36%	69.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$356.4M	-$342.1M	-$335.6M
YoY Change	4.18%	4.3%	3.49%
Common Stock	$6.000K	$6.000K	$5.000K
YoY Change	0.0%	20.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$94.79M	$98.68M	$51.21M
YoY Change
Total Liabilities & Shareholders Equity	$141.8M	$146.8M	$101.1M
YoY Change	-3.41%	93.26%	127.21%

Cashflow Statement

Concept	2020 Q2	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$6.344M	-$6.507M	-$5.136M
YoY Change	-2.5%	74.22%	9.42%
Depreciation, Depletion And Amortization	$462.0K	$430.0K	$319.0K
YoY Change	7.44%	65.38%	34.03%
Cash From Operating Activities	-$10.07M	-$5.060M	-$2.851M
YoY Change	99.01%	-36.35%	-31.88%
INVESTING ACTIVITIES
Capital Expenditures	-$730.0K	-$810.0K	$445.0K
YoY Change	-9.88%	-44.14%	2681.25%
Acquisitions
YoY Change
Other Investing Activities	-$1.000M	$0.00
YoY Change
Cash From Investing Activities	-$1.730M	-$810.0K	-$445.0K
YoY Change	113.58%	-44.14%	2681.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	120.0K	51.93M	-$2.082M
YoY Change	-99.77%	34.26%	-24.67%
NET CHANGE
Cash From Operating Activities	-10.07M	-5.060M	-$2.851M
Cash From Investing Activities	-1.730M	-810.0K	-$445.0K
Cash From Financing Activities	120.0K	51.93M	-$2.082M
Net Change In Cash	-11.68M	46.06M	-$5.378M
YoY Change	-125.36%	57.31%	-22.79%
FREE CASH FLOW
Cash From Operating Activities	-$10.07M	-$5.060M	-$2.851M
Capital Expenditures	-$730.0K	-$810.0K	$445.0K
Free Cash Flow	-$9.340M	-$4.250M	-$3.296M
YoY Change	119.76%	-34.62%	-21.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001200375
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P6M
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34705
	dei	Entity Registrant Name EntityRegistrantName	Codexis, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	71-0872999
	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Penobscot Drive,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	421-8100
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	CDXS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59126820	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75649000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90498000	USD
CY2020Q2	us-gaap	Restricted Cash RestrictedCash	619000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	661000	USD
CY2020Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	14035000	USD
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9063000	USD
CY2020Q2	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	1027000	USD
CY2020Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	12412000	USD
CY2019Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	10099000	USD
CY2020Q2	us-gaap	Notes Receivable Gross NotesReceivableGross	26447000	USD
CY2019Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	20189000	USD
CY2020Q2	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	34000	USD
CY2019Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	34000	USD
CY2020Q2	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	26413000	USD
CY2019Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	20155000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	686000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	371000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3131000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2520000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	106498000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	114205000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1062000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1062000	USD
CY2020Q2	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	1000000	USD
CY2019Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	0	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22599000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23837000	USD
CY2020Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	170000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	268000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	3241000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3241000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	391000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	178000	USD
CY2020Q2	us-gaap	Assets Assets	141783000	USD
CY2019Q4	us-gaap	Assets Assets	149073000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2637000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2621000	USD
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4979000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5003000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6943000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6943000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6540000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2482000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1107000	USD
CY2020Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	60000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1903000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	57000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	18944000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15388000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3142000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1987000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23665000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24951000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1246000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1230000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Liabilities Liabilities	46997000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	43556000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59125000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59125000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58877000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58877000	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	451185000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	447920000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356405000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-342409000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	94786000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	105517000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141783000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	149073000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14967000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12319000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29637000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27901000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1699000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2772000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4240000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7163000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10853000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8274000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21820000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16290000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8522000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7896000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17512000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16311000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	21074000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	18942000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	43572000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	39764000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6107000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6623000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13935000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11863000	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	57000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	220000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	323000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	450000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-88000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-72000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-211000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6037000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-6491000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13684000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11624000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	307000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	312000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-6344000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6507000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13996000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11643000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59000000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54954000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58944000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54564000	shares
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	99066000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	158000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1935000	USD
CY2020Q2	cdxs	Adjustments To Additional Paid In Capital Non Employee Share Based Compensation AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation	4000	USD
CY2020Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	33000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-6344000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	94786000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	51210000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2067000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1988000	USD
CY2019Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	74000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	49926000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6507000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	98684000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	105517000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	197000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4104000	USD
	cdxs	Adjustments To Additional Paid In Capital Non Employee Share Based Compensation AdjustmentsToAdditionalPaidInCapitalNonEmployeeShareBasedCompensation	4000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1040000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13996000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	94786000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	56306000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2843000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4051000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2799000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	74000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	49926000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11643000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	98684000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13996000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11643000	USD
	us-gaap	Depreciation Depreciation	900000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	611000	USD
	us-gaap	Depreciation Depreciation	693000	USD
	cdxs	Lease Rightof Use Asset Amortization LeaseRightofUseAssetAmortization	1336000	USD
	cdxs	Lease Rightof Use Asset Amortization LeaseRightofUseAssetAmortization	1486000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4108000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4051000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-168000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4972000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	262000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-1027000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-35000	USD
	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	2313000	USD
	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	-365000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	315000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	131000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	213000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-59000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-19000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	882000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1625000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-24000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-721000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1863000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	402000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1270000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-715000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3001000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	812000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11498000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7909000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1490000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1258000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1000000	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2490000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1257000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	197000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2843000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	50000000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	74000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	60000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	119000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1040000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2799000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-903000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49851000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14891000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40685000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92221000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54485000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77330000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95170000	USD
	us-gaap	Interest Paid Net InterestPaidNet	4000	USD
	us-gaap	Interest Paid Net InterestPaidNet	9000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	5000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	90000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	773000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75649000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93421000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1681000	USD
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1749000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77330000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95170000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In these notes to the unaudited condensed consolidated financial statements, the “Company,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which we have been continuously improving since our inception in 2002, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers.</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a pioneer in the harnessing of computational technologies to drive biology advancements. Since 2002, we have made substantial investments in the development of our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants’ performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development which are all coordinated to create our novel protein innovations.</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our approach to developing commercially viable biocatalytic manufacturing processes begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized protein catalysts to enable that process design, using our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering platform technology. Engineered protein catalyst candidates - many thousands for each protein engineering project - are then rapidly screened and validated in high throughput screening under relevant manufacturing operating conditions. This approach results in an optimized protein catalyst enabling cost-efficient processes that typically are relatively simple to run in conventional manufacturing equipment. This also allows for the efficient technical transfer of our process to our manufacturing partners.</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The successful embodiment of our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those directly involved in practicing our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering platform technology, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, fermentation process development and fermentation engineering. Our integrated, multi-disciplinary approach to biocatalyst and process development is a critical success factor for the Company.</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We initially commercialized our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering technology platform and products in the pharmaceuticals market, which remains a primary business focus. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also licensed our proprietary CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">® </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">protein engineering technology platform to global pharmaceutical companies so that they may in turn use this technology to engineer enzymes for their own businesses. Most recently, in May 2019, we entered into a Platform Technology Transfer and License Agreement (the “Novartis CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Agreement”) with Novartis Pharma AG (“Novartis”). The Novartis CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">® </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Agreement allows Novartis to use our proprietary CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering platform technology in the field of human healthcare.</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As evidence of our strategy to extend our technology beyond pharmaceutical manufacturing, we have also used the technology to develop protein catalysts and industrial enzymes for use in a wider set of industrial markets. These target industries consist of several large market verticals, including food and food ingredients, animal feed, consumer care, flavors, fragrances and agricultural chemicals. In addition, we are using our technology to develop enzymes for customers using next generation sequencing ("NGS") and polymerase chain reaction ("PCR/qPCR") for in vitro molecular diagnostic and genomic research applications. In December 2019, we entered into a license agreement to provide Roche Sequencing Solutions, Inc. (“Roche”) with our first enzyme for this target market, the Company's EvoT4™ DNA ligase. In June 2020, we entered into a co-marketing and enzyme supply collaboration agreement with Alphazyme LLC for the production and co-marketing of enzymes for life science applications including, initially, high-fidelity DNA polymerase, T7 RNA polymerase and reverse transcriptase enzymes.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have also begun using the CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both for our customers and for our own business. In October 2017, we entered into the "Nestlé Agreement” with Nestlé Health Science to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of phenylketonuria ("PKU"). PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In March 2020, we entered into a Strategic Collaboration and License Agreement (“Takeda Agreement”) with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”), for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor deficiencies. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span></div><div style="text-indent:18pt;margin-top:12pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Below are brief descriptions of our business segments:</span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Performance Enzymes</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We initially commercialized our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">® </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, consumer care, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. </span></div><div style="text-indent:36pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Novel Biotherapeutics</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity.</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our first lead program was for the potential treatment of hyperphenylalaninemia (“HPA”) (also referred to as PKU) in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a global development, option and license agreement with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration that it had completed its review of our investigational drug application for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. In January 2020, we and Nestlé Health Science entered into a development agreement pursuant to which we and Nestlé Health Science are collaborating to advance a lead candidate targeting a gastro-intestinal disorder discovered through our Strategic Collaboration Agreement into pre-clinical and early clinical studies. The Strategic Collaboration Agreement was extended through December 2021. Using our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering platform technology, we have also developed a pipeline of other biotherapeutic drug candidates, all of which are in preclinical development. </span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our most recent achievement in novel biotherapeutics came in March 2020, when we announced a strategic collaboration and license agreement with Takeda in which we will collaborate with Takeda to research and develop protein sequences for use in gene therapy products for certain disease indications. Under the terms of the Takeda Agreement, we will generate novel gene sequences encoding protein variants tailored to enhance efficacy as a result of increased activity, stability, and cellular uptake using our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> protein engineering platform. Takeda will combine these improved transgenes with its gene therapy capabilities to generate novel candidates for the treatment of rare genetic disorders. We are currently collaborating on three initial programs for the treatment of Fabry disease, Pompe disease, and an unnamed blood factor deficiency. The Company is responsible for the creation of novel enzyme sequences for advancement as gene therapies into pre-clinical development. Takeda is responsible for the pre-clinical and clinical development and commercialization of gene therapy products resulting from the collaboration programs. Under the terms of the agreement, in addition to the three initial programs, Takeda may initiate up to four additional programs for separate target indications. In March 2020, we began research and development activities under the program plans and received a $8.5 million one-time, non-refundable cash payment.</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to make additional investments in our pipeline with the aim of advancing additional product candidates targeting other therapeutic areas. </span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For additional discussion of our business segments, see Note 13, "Segment, Geographical and Other Revenue Information."</span></div><div style="text-indent:18pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Business Update Regarding COVID-19</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to risks and uncertainties as a result of the current COVID-19 pandemic. The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, communities and business operations, as well as the U.S. economy and other economies worldwide. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including the duration and severity of the pandemic and the extent and severity of the impact on our customers, new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we and our collaboration partners have been able to continue to supply our enzymes to our customers worldwide. However, we are dependent on our manufacturing and logistics partners and consequently, disruptions in operations of our partners and customers may affect our ability to supply enzymes to our customers. Furthermore, our ability to provide future research and development ("R&D") services will continue to be impacted as a result of governmental orders and any disruptions in operations of our customers with whom we collaborate. We are continuing to assess the potential impact of the COVID-19 pandemic on our business and operations, including our product sales, R&D service revenue, expenses and manufacturing. However, we are unable to fully determine and quantify the extent to which this pandemic affected our total revenues due to complex accounting judgments.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the U.S., the impact of COVID-19, including governmental orders ("Orders") governing the operation of businesses during the pandemic, caused the temporary closure of our Redwood City, California facilities and has disrupted our research and development operations. Research and development operations for all other projects were temporarily suspended from mid-March 2020 through the end of April in accordance with these Orders. In May 2020, we initiated limited operations and gradually ramped up our R&D operations so that we are currently utilizing the majority of our normal R&D capacity. Additionally, we have resumed small scale manufacturing at our Redwood City pilot plant in May 2020.</span></div><div style="text-indent:22.5pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that we may undertake to address financial and operations challenges faced by our customers. As of the date of issuance of the unaudited condensed consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact our financial condition, liquidity, or results of operations is uncertain in the future.</span></div><div style="margin-top:12pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%;">Recent Investing Activities</span></div><div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2020, we entered into a Master Collaboration and Research Agreement with Molecular Assemblies, Inc. (“MAI”), a privately held company, to engineer enzymes to deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA (“MAI Agreement”). Under an associated stock purchase agreement, we purchased 1,587,050 shares of MAI's Series A preferred stock for $1.0 million, and in connection with our investment, John Nicols, our chief executive officer joined MAI’s board of directors. Under the MAI Agreement, for a fixed monthly fee payable in shares of Series A preferred stock, we will apply our CodeEvolver</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">® </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">protein engineering platform technology to improve the DNA polymerase enzymes that are critical for enzymatic DNA synthesis. Through the provision of these services, we are eligible to earn additional shares of Series A preferred stock. MAI will combine its advanced chemistries with our enzymes to drive the process to commercialization. For additional information, see Note 12,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> "</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Related Party Transactions," in the Notes to Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, the interest rate used to adjust the promised amount of consideration for the effects of significant financial assets (comprised of accounts receivable, contract assets, and unbilled receivables), inventories, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the unaudited condensed consolidated financial statements. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers, markets and economies.</span></div>
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	reportingUnit
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	reportingUnit
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	reportingUnit
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14967000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12319000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14967000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12319000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29637000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27901000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29637000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27901000	USD
CY2020Q2	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Asset Gross Current ContractWithCustomerAssetGrossCurrent	1027000	USD
CY2020Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	12412000	USD
CY2019Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	10099000	USD
CY2020Q2	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	172000	USD
CY2019Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	0	USD
CY2020Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5045000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2044000	USD
CY2020Q2	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	USD
	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	USD
	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	USD
CY2019Q2	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	USD
CY2020Q2	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	4272000	USD
	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	3752000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	1367000	USD
	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	57000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	1357000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	-92000	USD
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	637000	USD
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	43000	USD
CY2020Q2	cdxs	Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition	9338000	USD
CY2019Q2	cdxs	Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition	11044000	USD
	cdxs	Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition	28943000	USD
	cdxs	Contractwith Customer Liability New Activities Performance Obligation Satisfied Revenue Recognition ContractwithCustomerLiabilityNewActivitiesPerformanceObligationSatisfiedRevenueRecognition	24106000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	14967000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12319000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	29637000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	27901000	USD
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1674000	USD
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1009000	USD
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2362000	USD
CY2020Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5045000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75600000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90500000	USD
CY2020Q2	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	1000000.0	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33567000	USD
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	77000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7000	USD
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	28000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	26000	USD
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	581000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	338000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	686000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	371000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	40389000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	39533000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33251000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6822000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6282000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	3200000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2020Q2	us-gaap	Purchase Obligation PurchaseObligation	3669000	USD
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	4386000	USD
CY2020Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	2949000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	1802000	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	325000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	352000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6943000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6540000	USD
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1939000	USD
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1988000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4108000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4051000	USD
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1939000	USD
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1988000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4108000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4051000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	32749	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	529187	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.03
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.37
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2800000	USD
CY2020Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	77300	sqft
CY2020Q2	us-gaap	Number Of Properties Subject To Ground Leases NumberOfPropertiesSubjectToGroundLeases	4	security
CY2020Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	200000	USD
CY2020Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	200000	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0	USD
CY2019	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0	USD
CY2017Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	400000	USD
CY2017Q1	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2017Q2	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2017Q2	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	300000	USD
CY2017Q2	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2020Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	45000	USD
CY2019Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	54000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	99000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	109000	USD
CY2020Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	USD
CY2019Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000	USD
CY2020Q2	cdxs	Finance Lease Cost FinanceLeaseCost	46000	USD
CY2019Q2	cdxs	Finance Lease Cost FinanceLeaseCost	57000	USD
	cdxs	Finance Lease Cost FinanceLeaseCost	100000	USD
	cdxs	Finance Lease Cost FinanceLeaseCost	115000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1032000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1100000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2100000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2278000	USD
CY2020Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	16000	USD
CY2019Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	47000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	774000	USD
CY2020Q2	us-gaap	Sublease Income SubleaseIncome	0	USD
CY2019Q2	us-gaap	Sublease Income SubleaseIncome	254000	USD
	us-gaap	Sublease Income SubleaseIncome	55000	USD
	us-gaap	Sublease Income SubleaseIncome	465000	USD
CY2020Q2	us-gaap	Lease Cost LeaseCost	1094000	USD
CY2019Q2	us-gaap	Lease Cost LeaseCost	903000	USD
	us-gaap	Lease Cost LeaseCost	2192000	USD
	us-gaap	Lease Cost LeaseCost	1928000	USD
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066
	us-gaap	Operating Lease Payments OperatingLeasePayments	1633000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	0	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	6000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	60000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	119000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2042000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4197000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4285000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4589000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4726000	USD
CY2020Q2	cdxs	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	13494000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	33333000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7186000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	26147000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14967000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12319000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29637000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27901000	USD
CY2019Q4	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	34000	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	USD
CY2020Q2	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	34000	USD
CY2020Q2	us-gaap	Financing Receivable Recorded Investment Past Due FinancingReceivableRecordedInvestmentPastDue	1039000	USD
CY2020Q2	us-gaap	Financing Receivable Recorded Investment Current FinancingReceivableRecordedInvestmentCurrent	12996000	USD
CY2020Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	14035000	USD
CY2019Q4	us-gaap	Financing Receivable Recorded Investment Past Due FinancingReceivableRecordedInvestmentPastDue	257000	USD
CY2019Q4	us-gaap	Financing Receivable Recorded Investment Current FinancingReceivableRecordedInvestmentCurrent	8806000	USD
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9063000	USD

Files In Submission

Name	View Source	Status
0001200375-20-000033-index-headers.html	Edgar Link	pending
0001200375-20-000033-index.html	Edgar Link	pending
0001200375-20-000033.txt	Edgar Link	pending
0001200375-20-000033-xbrl.zip	Edgar Link	pending
cdxs-20200630.htm	Edgar Link	pending
cdxs-20200630.xsd	Edgar Link	pending
cdxs-20200630_cal.xml	Edgar Link	unprocessable
cdxs-20200630_def.xml	Edgar Link	unprocessable
cdxs-20200630_htm.xml	Edgar Link	completed
cdxs-20200630_lab.xml	Edgar Link	unprocessable
cdxs-20200630_pre.xml	Edgar Link	unprocessable
cdxs20200630ex311sp.htm	Edgar Link	pending
cdxs20200630ex312sp.htm	Edgar Link	pending
cdxs20200630ex321sp.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXS
CODEXIS, INC. Stock $cdxs

2020 Q2 Form 10-Q Financial Statement

#000120037520000033 Filed on August 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS CODEXIS, INC. Stock $cdxs

2020 Q2 Form 10-Q Financial Statement

#000120037520000033 Filed on August 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXS
CODEXIS, INC. Stock $cdxs